(Q38773370)

6 September 2017

0 references

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis (English)

1 reference

6 September 2017

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Pedro F. Oliveira

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Pedro N Aguiar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hakaru Tadokoro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gilberto de Lima Lopes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Bruno Andraus Filardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giannis Mountzios

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ramon Andrade de Mello

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 April 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

479-488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Optimal first-line and maintenance treatments for advanced-stage nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Immunotherapy and lung cancer: current developments and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0002

21 January 2018

Identifiers

DOI

10.2217/IMT-2015-0002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26973128%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference